Sort   by:  
 Page size 
TranscriptomicsTKI258_FGFR_INHIBITOR_TREATMENT
New targets and drugs for treatment of breast cancer are needed. We tested the effects of the TKI258 (Novartis) FGFR-inhibitor on tumor formation in mice. 4T1 mouse cell line, which had been derived from BALB/c mice, was injected into tail veins of BALB/c mice (syngraft model). Seven days later, mic...
ORGANISM(S): Mus musculus 
2013-02-17 | E-MTAB-1260 | biostudies-arrayexpress
TranscriptomicsRNA-seq analysis of primary human cancer associated fibroblasts isolated from breast cancer tissue
Primary human cancer associated fibroblasts (CAFs) were isolated and cultivated (up to passage 10). CAFs were sequenced to find differences in their respective gene expression patters.
ORGANISM(S): Homo sapiens 
2021-02-03 | E-MTAB-10075 | biostudies-arrayexpress
ProteomicsmiR-1307-5p counteracts breast cancer angiogenesis and metastasis
MiRNAs have been shown to alter both protein expression and secretion in different cellular contexts. By combining in vitro, in vivo and in silico techniques, we demonstrated that overexpression of pre-miR-1307 reduced the ability of breast cancer cells to induce endothelial cell sprouting and angio...
ORGANISM(S): Homo sapiens (Human) 
2024-12-11 | PXD041087 | Pride
Breast cancer Cell culture supernatant Dia Mda-mb-231 Sp3 Mir-1307 Human Secretome 
ProteomicsHuman MDA-MB-231 breast cancer cells overexpressing miR-183-5p and its isomiRs
Overexpression of miR-183-5p|+2, but not of the other two isomiRs |0 and |+1, was observed to reduce cell cycle and cell proliferation in different triple-negative breast cancer cell lines. Therefore, we hypothesized that the |+2 isoform has targets distinct from the other two isoforms. To test this...
ORGANISM(S): Homo sapiens (Human) 
2022-05-26 | PXD026763 | Pride
Human Breast cancer Mir-183-5p Mirna Mda-mb-231 
ModelsMammalian Cell Cycle
BACKGROUND: In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal antibody trastuzumab in adjuvant settings; however, de novo resistance to t...
1607 | Cell Collective
ProteomicsPAK1 activation as a common mechanism of endocrine therapy resistance in luminal A breast cancer models
Breast cancer is a highly heterogeneous disease, representing the most frequent malignancy and the second leading cause of cancer-related mortality in women worldwide. Among breast cancer subtypes, estrogen receptor-positive (ER+) tumors are often treated with endocrine therapies such as Tamoxifen o...
ORGANISM(S): Homo sapiens (Human) 
2026-02-13 | PXD063393 | Pride
Endocrine therapy Breast cancer Therapy resistance Phosphoproteomics 
TranscriptomicsMethylome profiling of MCF7 parental and long-term estrogen deprived cell lines
MCF7 (parental) cells were cultivated in estrogen deprived media for 12 months (long-term estrogen deprivation - LTED), until they had regained proliferative capacity (proxy for resistance to aromatase inhibition). Methylomes of parental and LTED MCF7 cells were analyzed to identify differentially m...
ORGANISM(S): Homo sapiens 
2025-10-27 | E-MTAB-15519 | biostudies-arrayexpress
ProteomicsPhosphoproteomics measurement of clonal endocrine therapy sensitive and resistant breast cancer populations
Around two thirds of breast tumors are characterized by the expression of estrogen receptor α and are therapeutically treated by blocking estrogen signaling. First line endocrine therapeutics are Tamoxifen which displaces estrogen form its receptor preventing receptor activation and aromatase inhibi...
ORGANISM(S): Homo sapiens (Human) 
2024-01-26 | PXD040478 | Pride
Phosphoproteomics Clonal deconvolution Breast cancer Therapy resistance 
ProteomicsGYLATL1 promotes endocrine therapy resistance in luminal A-like breast cancer and is regulated by estrogen-independent ERα signaling
Luminal A breast cancer is characterized by the expression and activity of estrogen receptor-α (ERα), a biomarker and therapeutic target. While endocrine therapies targeting ER signaling have shown efficacy, long-term success is limited by the development of resistance. Almost 40% of ER-positive bre...
ORGANISM(S): Homo sapiens (Human) 
2026-01-30 | PXD067936 | Pride
Breast cancer Prm Glyatl1 Endocrine therapy resistance Dia 
TranscriptomicsGenes affected by manipulation of LIMT, a novel metastasis inhibiting lncRNA is suppressed by EGF and down-regulated in aggressive breast cancer
The long non coding RNA LIMT was found in our study to inhibit cellular migration in vitro and to inhibit colonization of mammary tumorigenic cells in lungs of mice in vivo. In order to uncover the mechanism enabling these tumor suppressive functions of LIMT the expression of this lncRNA was knocked...
ORGANISM(S): Homo sapiens 
2017-07-27 | E-MTAB-4821 | biostudies-arrayexpress
Sort   by:  
 Page size